The discussion will be open to the public.

WILLIAM P. KELLY, Jr.,
Commissioner,
Federal Supply Service.

[FR Doc. 78-33188 Filed 11-27-78; 8:45 am]

[6820-22-M]

REGIONAL PUBLIC ADVISORY PANEL ON ARCHITECTURAL AND ENGINEERING SERVICES

Meeting

NOVEMBER 24, 1978.

"Pursuant to Public Law 92-463, notice is hereby given of a meeting of the Regional Public Advisory Panel on Architectural and Engineering Services, Central Office, December 11 and December 12, 1978, from 9:00 A.M. to 4:00 P.M., Room 5206, General Services Administration, 18th & F Streets NW., Washington, D.C. The meeting will be devoted to the initial step of the procedures for screening and evaluating the qualifications of architect-engineers under consideration for selection to furnish professional services for the proposed Smithsonian Institution Museum Support Center, Suitland, Maryland. The meeting will be open to the public." In order to meet the schedule requirements of the full committee, it will be necessary to hold the meeting on the specified dates.

DAVID R. DIBNER,
Acting Commissioner.

[FR Doc. 78-33406 Filed 11-27-78; 8:45 am]

[6820-38-M]

[Federal Property Management Regs., Temporary Regulation E-54]

SECRETARY OF DEFENSE

Delegation of Authority

1. *Purpose.* This regulation delegates authority to the Secretary of Defense to represent the interests of the executive agencies of the Federal Government in a gas rate increase proceeding.

2. *Effective date.* This regulation is effective immediately.

3. *Delegation.*

a. Pursuant to the authority vested in me by the Federal Property and Administrative Services Act of 1949, 63 Stat. 377, as amended, particularly sections 201(a)(4) and 205(d) (40 U.S.C. 481(a)(4) and 486(d)), authority is delegated to the Secretary of Defense to represent the consumer interests of the executive agencies of the Federal Government before the Oklahoma Corporation Commission involving the application of the Arkansas Louisiana Gas Company for an increase in rates.

b. The Secretary of Defense may redelegate this authority to any officer, official, or employee of the Department of Defense.

c. This authority shall be exercised in accordance with the policies, procedures, and controls prescribed by the General Services Administration, and shall be exercised in cooperation with the responsible officers, officials, and employees thereof.

JAY SOLOMON,
Administrator of
General Services.

NOVEMBER 10, 1978.

[FR Doc. 78-33208 Filed 11-27-78; 8:45 am]

[4110-88-M]

DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE

Alcohol, Drug Abuse, and Mental Health Administration

BIOLOGICAL SCIENCES TRAINING REVIEW COMMITTEE

Meeting Change

In FR Doc. 78-31506 appearing on page 52061 in the issue of Wednesday, November 8, 1978, the Notice is changed as follows:

BIOLOGICAL SCIENCES TRAINING REVIEW COMMITTEE

December 20-22, 9 a.m., Conference Room I, Parklawn Building, 5600 Fishers Lane, Rockville, Md. 20857. Open: December 20, 9-10 a.m. Closed: Otherwise.

All other information remains as announced November 8.

Dated: November 21, 1978.

ELIZABETH A. CONNOLLY,
Committee Management Officer,
Alcohol, Drug Abuse, and
Mental Health Administration.

[FR Doc. 78-33212 Filed 11-27-78; 8:45 am]

[4110-88-M]

NATIONAL ADVISORY COUNCIL ON DRUG ABUSE

Meeting

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (5 U.S.C. Appendix I), announcement is made of the following National advisory body scheduled to assemble during the month of January 1979:

NATIONAL ADVISORY COUNCIL ON DRUG ABUSE

January 25-26, 1979, Conference Room G-H, Parklawn Building, 5600 Fishers Lane, Rockville, Md. 20857. Closed: 9:30-noon, January 25. Open: Otherwise. Contact: Ms. Mary E. Kielkopf, Room 10A-23, Parklawn Building, 5600 Fishers Lane, Rockville, Md. 20857, 301-443-6618.

Purpose. The National Advisory Council on Drug Abuse advises and makes recommendations to the Secretary, Department of Health, Education, and Welfare, the Administrator, Alcohol, Drug Abuse, and Mental Health Administration, and the Director, National Institute on Drug Abuse, on the development of new initiatives and priorities, and the efficient administration of drug abuse research, training, demonstration, prevention, and community services programs. The Council also gives advice on policies and priorities for drug abuse grants and contracts, and reviews and makes recommendations on grant applications.

Agenda. From 9:30 a.m. to 12 Noon, January 25, the meeting shall be closed for final review of grant applications for Federal assistance in accordance with the determination by the Administrator, Alcohol, Drug Abuse, and Mental Health Administration, pursuant to the provisions of Title 5, U.S. Code 552b(c)(6), and Section 10(d) of Pub. L. 92-463 (5 U.S.C. Appendix I).

The remainder of the meeting from 1:30 p.m. on January 25 until adjournment on January 26 will be open to the public for a discussion of issues in the field of drug abuse, and administrative announcements. Discussions around drug paraphernalia, priority scores for grant applications, and a report from the National Association of State Alcohol and Drug Abuse Directors are planned. Agenda items are subject to change as priorities dictate.

Substantive program information, summaries of the meeting, and roster of the Council members may be obtained from the contact person listed above.

Dated: November 21, 1978.

ELIZABETH A. CONNOLLY,
Committee Management Officer,
Alcohol, Drug Abuse, and
Mental Health Administration.

[FR Doc. 78-33213 Filed 11-27-78; 8:45 am]

[1505-01-M]

Food and Drug Administration

[Docket No. 78N-0263]

ANTACID DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE

Final Classification of Category III Antacid Ingredients and Labeling Claims

Correction

In FR Doc. 78-24914 appearing on page 39427 in the issue of Tuesday, September 5, 1978, in the 1st column under SUPPLEMENTARY INFOR-

MATION, the 9th line in paragraph (i) in small type should read as follows:

". . . directions for use, prescription or OTC . . .".

[4110-03-M]

Food and Drug Administration

CONAGRA, INC.

Boost-O-Iron; Withdrawal of Approval of New Animal Drug Application

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The agency withdraws approval of new animal drug application (NADA) providing for use of Boost-O-Iron (20 percent ferrous fumarate), a product intended for use in the prevention of iron deficiency anemia in infant pigs. This action is taken in response to a request by ConAgra, Inc., the sponsor.

EFFECTIVE DATE: November 28, 1978.

FOR FURTHER INFORMATON CONTACT:

David N. Scarr, Bureau of Veterinary Medicine (HRV-214), Food and Drug Administration, Department of Health, Education, and Welfare, 5600 Fishers Lane, Rockville, MD 20857, 301-443-1846.

SUPPLEMENTARY INFORMATION: ConAgra, Inc., 3801 Harney St., Omaha, NE 68131, is the sponsor of NADA 31-876 providing for Boost-O-Iron (20 percent ferrous fumarate), which is intended for use in the prevention of iron deficiency anemia in infant pigs. The application was originally approved on February 14, 1967.

The sponsor informed the agency that the product was never manufactured, requested withdrawal of approval of the application, and waived opportunity for a hearing by letter of April 17, 1978.

Therefore, under the Federal Food, Drug, and Cosmetic Act (sec. 512(e), 82 Stat. 345-347 (21 U.S.C. 360b(e))) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.1), and redelegated to the Director of the Bureau of Veterinary Medicine (21 CFR 5.84), and in accordance with § 514.115 *Withdrawal of approval of applications* (21 CFR 514.115), notice is given that approval of NADA 31-876 and all supplements for Boost-O-Iron is hereby withdrawn, effective November 28, 1978.

Published elsewhere in this issue of the FEDERAL REGISTER is a final order revoking § 558.258 *Ferrous fumarate* (21 CFR 558.258) to reflect withdrawal of approval of this application.

Dated: November 17, 1978.

LESTER M. CRAWFORD,
Acting Director, Bureau of Veterinary Medicine.

[FR Doc. 78-33090 Filed 11-27-78; 8:45 am]

[4110-03-M]

[Docket No. 78N-0306; DESI 10670]

TOLBUTAMIDE

Drugs for Human Use; Drug Efficacy Study Implementation; Followup Notice

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: This notice states the conditions for marketing tolbutamide for the indication for which it is regarded as effective, allowing for the submission of abbreviated new drug applications (ANDA's). The drug is an oral hypoglycemic agent.

DATE: Supplements to approved new drug applications (NDA's) due on or before January 29, 1978.

ADDRESSES: Communications forwarded in response to this notice should be identified with the reference number DESI 10670, directed to the attention of the appropriate office named below, and addressed to the Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857.

Supplements to full new drug applications (identify with NDA number); Division of Metabolism and Endocrine Drug Products (HFD-130), Rm. 14B-04, Bureau of Drugs.

Original abbreviated new drug applications of supplements thereto (identify as such): Division of Generic Drug Monographs (HFD-530), Bureau of Drugs.

Requests for the report of the National Academy of Sciences-National Rsearch Council: Public Records and Document Center (HFI-35), Rm. 4-62.

Requests for opinion of the applicability of this notice to a specific product: Division of Drug Labeling Compliance (HFD-310), Bureau of Drugs.

Other communications regarding this notice: Drug Efficacy Study Implementation Project Manager (HFD-501), Bureau of Drugs.

FOR FURTHER INFORMATION CONTACT:

Herbert Gerstenzang, Bureau of Drugs (HFD-32), Food and Drug Administration, Department of Health, Education, and Welfare, 5600 Fishers Lane, Rockville, Md 20857, 301-443-3650.

SUPPLEMENTARY INFORMATION: In a notice (DESI 10670) published in the FEDERAL REGISTER of September 27, 1968 (33 FR 14551), the Food and Drug Administration, having evaluated the drug described below, announced its conclusion that tolbutamide is effective for its labeled indication.

NDA 10-;670; Orinase TAblets containing tolbutamide; The Upjohn Co., 7171 Portage Rd., Kalamazoo, MI 49002.

The following new drug application was not included in the initial notice, but is affected by this notice.

NDA 12-678; Tolbutamide Tablets; Premo Pharmaceutical Laboratories, Inc., 111 Leuning St., South Hackensack, NJ 07606.

The September 27, 1968 notice also stated that an approved new drug application is required for marketing the drug product. At that time the new drug application had to contain full information as required by the new drug application form FD-356H (21 CFR 314.1(c)). Upon reevaluating the requirement of full new drug applications for tolbutamide, the director of the Bureau of Drugs concludes that abbreviated new drug applications (21 CFR 314.1(f)) are appropriate for the drug.

Labeling for oral hypoglycemic drugs is presently undergoing revision. Proposed labeling was published in the FEDERAL REGISTER of July 7, 1975 (40 FR 28587). The September 27, 1968 notice contained full labeling for tolbutamide. As the full labeling is now under review, only the indications section is included in this notice. The current indication is as follows: "Tolbutamide is indicated in uncomplicated diabetes mellitus of the stable, mild, or moderately severe, nonketotic, naturity-onset type that cannot be completely controlled by diet alone." When the review of the labeling for oral hypoglycemic drugs is finalized, revision of the indication may be required.

Accordingly, the September 27, 1968 notice is amended to read as follows:

Such drugs are regarded as new drugs (21 U.S.C. 321(p)). Supplemental new drug applicatons are required to revise the labeling in and to update previously approved applications providing for such drugs. An approved new drug application is a requirement for marketing such a drug product.

In addition to the product specifically named above, this notice applies to any drug product that is not the subject of an approved new drug application and is identical to a similar or related drug product that is not the subject of an approved new drug application. It is the responsibility of every drug manufacturer or distributor to review this notice to determine whether it covers any drug product that the person manufactures or distributes.